Aktis Oncology, Inc. (AKTS)
18.14
+0.40
(+2.23%)
USD |
NASDAQ |
Oct 09, 16:00
18.14
0.00 (0.00%)
After-Hours: 18:33
Aktis Oncology Gross Profit Margin (Quarterly) : 74.02% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 74.02% |
| March 31, 2026 | 79.80% |
| December 31, 2025 | 62.83% |
| Date | Value |
|---|---|
| June 30, 2025 | 65.52% |
| March 31, 2025 | 66.55% |
| December 31, 2024 | 52.73% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 90.81% |
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| Savara, Inc. | -- |
| Vericel Corp. | 72.82% |
| Biogen, Inc. | 61.37% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -19.27% |
| Return on Assets | -16.17% |
| Return on Invested Capital | -18.72% |
| Profit Margin (Quarterly) | -713.5% |
| Operating Margin (Quarterly) | -854.0% |
| Return on Net Operating Assets | -271.7% |